Business Wire

Prima Solutions Strengthens Its Software Offering by Acquiring Tricast, Expert in Data Analysis Solutions and Predictive Algorithms for the Insurance Industry


In accordance with its ambitious international development strategy and with the support of The Carlyle Group, its new shareholder, Prima Solutions, French insurance software vendor, today announced the acquisition of Tricast, a company specialized in analysis and predictive tools.

This press release features multimedia. View the full release here:

Based in Paris and created in 2000 by Jean Boudy, Tricast partners with nearly 50 clients across a variety of countries in Europe, South America, the Middle East and Asia, offering them access to an fully-integrated insurance analysis software platform comprised of data and predictive algorithms and aimed at improving the market position and technical margins of its end users.

This acquisition will allow Prima Solutions to enrich its software offering and to market this customized technological and scientific capability, designed to optimize the results and operational efficiency of clients. On an international scale, this acquisition gives Prima Solutions the possibility of successfully reaching new markets within Europe, the Middle East, Latin America and Asia.

The merger of these 2 software platforms also strengthens Prima Solutions’ capacity to provide an insurance solution adapted to new on-demand insurance products linked to behavioral trends (such as ‘Pay how you drive’ and usage-based policies) and based on connected solutions. This capability is enabled by actuarial analysis of big data.

Following this acquisition, Tricast’s personnel will be fully employed by Prima Solutions and will be managed by the current executive team, including the President Hugues Delannoy, as well as the CEO Rodolphe Peim.

This agreement concluded with Prima Solutions has the objective of opening up a full-service digital software platform to insurance professionals, able to meet their operational needs, including the improvement of client relations, insurance policy management and claims handling, and, in addition, optimizing technical margins. Our clients will naturally continue to benefit from the same level of quality as they have up to now and will furthermore have access to Prima Solutions’ capabilities and innovative products,” stated Jean Boudy, Founder and CEO of Tricast.

We are delighted to welcome Tricast into the Prima Solutions group. This strategic match enables us to greatly strengthen our software offer while proposing a complementary expertise to our clients, which is central to the improvement of technical margins. This acquisition demonstrates our determination to pursue our new growth strategy, particularly on an international scale by targeting new markets beyond our initial borders, with the support of our new shareholder,” adds Hugues Delannoy, President of Prima Solutions.

The acquisition of Prima Solutions in partnership with its management team has now been finalized. The investment was made by Carlyle Europe Technology Partners III, a €657 million Carlyle fund focused on European technology, media and telecommunications (TMT) companies.


About Tricast
In order to improve the competitiveness and technical margins of insurers, banks, cooperatives and wholesalers, Tricast provides a range of analytical and simulation tools, which are technically innovative, scientifically sophisticated and easy to use:

  • Business monitoring, profit centre follow-up, business simulations, stress scenarios
  • Report generation, Insurance specific on-line dashboard with key performance indicators
  • Risks and clients segmentation, Cross and Up selling, Lapse rate reduction
  • Actuarial tools for pricing and reserving
  • Reinsurance optimization
  • Stimulations tools to analyse the consequences of decisions
  • Fraud detection

The Tricast software is used by management teams, who benefit from a comprehensive set of features and easy-to-use user interfaces. It is delivered as a single platform with a modular approach.
To learn more, visit

About Prima Solutions

Prima Solutions delivers the software platform Property and Casualty insurers need to gain in agility and succeed in a time of rapid industry change. Full web, modular, multilingual and available in SaaS mode, Prima Insure™ addresses the whole life cycle of an insurance policy: distribution; underwriting; contract; claims and financial management. More than 20 Property and Casualty insurers, including Allianz, AXA, Société Générale Insurance, PSA Insurance, CoverLife, Galian, Groupama, Hiscox, Mutuelle des Motards or Gras Savoye Willis, have already selected Prima Insure™. Prima Solutions is a member of ACORD.

About The Carlyle Group

The Carlyle Group (NASDAQ: CG) is a global alternative asset manager with $170 billion of assets under management across 299 investment vehicles as of June 30, 2017. Carlyle’s purpose is to invest wisely and create value on behalf of its investors, many of whom are public pensions. Carlyle invests across four segments – Corporate Private Equity, Real Assets, Global Market Strategies and Investment Solutions – in Africa, Asia, Australia, Europe, the Middle East, North America and South America. Carlyle has expertise in various industries, including: aerospace, defense & government services, consumer & retail, energy & power, financial services, healthcare, industrial, infrastructure, real estate, technology & business services, telecommunications & media and transportation. The Carlyle Group employs more than 1,550 people in 31 offices across six continents.


Contact information

Press contacts
Prima Solutions
Frédéric DUTREUIL, +33(0)1 70 91 13 16 / +33(0) 6 24 04 23 39
Leslia MADUBOST, +33(0)1 70 91 24 78
Steele&Holt (The Carlyle Group)
Daphne Claude & Dominic Riding
+33(0) 6 66 58 81 92 / +33(0) 6 57 48 83 24
Catherine Armstrong (The Carlyle Group)
+44(0)207 894 1632 / +44(0)7429 421 037

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 15:52Tiedote

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 15:50Tiedote

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 15:46Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 15:00Tiedote

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on

ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 14:27Tiedote

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi

Sofinnova Partners Leads SafeHeal’s €6 Million Series a Financing Round23.3.2018 10:00Tiedote

SafeHeal, an early-stage medtech company specialized in digestive surgery and focused on the development of the Colovac device, announces today that it has closed a €6 million Series A financing round led by Sofinnova Partners. Based in Paris, SafeHeal develops an innovative digestive anastomosis protection device, called Colovac, designed to reduce complications and obviate the need for ostomies for colectomy patients. This technology consists of a minimally invasive and fully reversible implant that remains in place until the body’s natural healing and tissue repair processes are complete, for approximately two weeks, after which it is removed. SafeHeal’s device has the potential to radically transform the market while significantly improve patients’ quality of life by enabling them to resume their normal life without having to bear an artificial anus and wear ostomy pouches for several months. About 270,000 colectomy patients receive an ostomy every year in Europe and the USA, repre

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme